Sarcoma News

Healio spoke with Sandra D’Angelo, MD, about a study of rogaratinib in patients with succinate dehydrogenase-deficient gastrointestinal stromal tumor presented at the Connective Tissue Oncology Society Annual Meeting.

Sandra D’Angelo, MD, talked about a study examining the role of tumor-infiltrating lymphocyte, or TIL, in metastatic sarcoma presented at the Connective Tissue Oncology Society Annual Meeting in a video interview.

In this video, Sandra D’Angelo, MD, discussed a phase 1b study on the efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma presented at the Connective Tissue Oncology Society Annual Meeting.

President Joe Biden today announced his intention to appoint oncologist, researcher and educator, W. Kimryn Rathmell, MD, PhD, as director of the NCI.

Positive results from a pivotal phase 2b trial showed mirdametinib significantly improved the outcomes of patients with neurofibromatosis type 1-associated plexiform neurofibromas, SpringWorks Therapeutics announced in a press release.

In a video interview, Sandra D’Angelo, MD, talked about a study of cabozantinib and temozolomide in patients with leiomyosarcoma and other soft tissue sarcomas, which was presented at the Connective Tissue Oncology Society Annual Meeting.

In this Healio interview, Sandra D’Angelo, MD, discussed two “interesting” studies for pigmented villonodular synovitis, or PVNS, presented at the Connective Tissue Oncology Society Annual Meeting.

Sandra D’Angelo, MD, discussed initial phase 1A/1B data from a clinical trial on the efficacy and safety of BI-907828, a MDM2 inhibitor, in patients with liposarcoma presented at the Connective Tissue Oncology Society Annual Meeting.

A CDK9 inhibitor, known as KB-0742, showed preliminary evidence of clinical activity in patients with various sarcomas, according to a study presented at the Connective Tissue Oncology Society Annual Meeting.

Sandra D’Angelo, MD, talked about preliminary results from a phase 1 study of FHD-609, a bromodomain-containing protein 9 degrader, in patients with advanced synovial sarcoma or SMARCB1-loss tumors in a video interview with Healio.